Its difficult to make direct comparisons between any individual trials with differing inclusion and exclusion criteria. In the case of aviptadil it is exacerbated by the fact that they have several groups, and the reporting of their data was sloppy.

specifically the trial group was defined as critical patients, but with many exclusions. Leronlimab was severe and critical, with significantly less exclusions.

Its difficult to compare these, two, but if you put the Aviptadil numbers in with the dozen or so other studies that we have discussed a larger overall picture begins to emerge, which suggests that the comparative groups range from 30-35% mortality.

At the end of the day, this is the very reason that we have a placebo group in each trial. To eliminate the variability. Once our data is out, we will know.